Stockreport

Antisense and RNAi Therapeutics Market to Reach USD 18.48 Billion by 2032, Growth Driven by Rising Prevalence of Genetic Diseases and Advances in Precision Medicine — SNS Insider [Yahoo! F...

Alnylam Pharmaceuticals, Inc.  (ALNY) 
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.alnylam.com/investor-overview
PDF in 2023 to USD 18.48 billion by 2032, at a compound annual growth rate (CAGR) of 18.05%. Austin, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Antisense and RNAi Therapeutics Mark [Read more]